ESCC Clinical Trials

8 recruiting

ESCC Trials at a Glance

24 actively recruiting trials for escc are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 12 trials, with the heaviest enrollment activity in Shanghai, Tianjin, and Fairfax. Lead sponsors running escc studies include City of Hope Medical Center, Sichuan University, and Bristol-Myers Squibb.

Browse escc trials by phase

Treatments under study

About ESCC Clinical Trials

Looking for clinical trials for ESCC? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ESCC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ESCC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 2

Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
Second Affiliated Hospital of Zunyi Medical University92 enrolled1 locationNCT07559045
Recruiting
Phase 2

Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
University Hospital, Clermont-Ferrand95 enrolled30 locationsNCT07205731
Recruiting
Phase 3

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
Qilu Pharmaceutical Co., Ltd.466 enrolled1 locationNCT07463573
Recruiting
Phase 1

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Head and Neck CancerHNSCCColo-rectal Cancer+4 more
ALX Oncology Inc.170 enrolled7 locationsNCT07085091
Recruiting
Phase 2

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma (ESCC)
Beijing Konruns Pharmaceutical Co., Ltd.60 enrolled1 locationNCT07481058
Recruiting
Phase 2

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)Locally Advanced Unresectable Esophageal Cancer
Ming-Yu Lien45 enrolled8 locationsNCT07039162
Recruiting
Phase 1

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Ovarian CancerCervical CancerEndometrial Cancer+6 more
Normunity AccelCo, Inc.150 enrolled9 locationsNCT07182149
Recruiting
Phase 2

Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma

ESCCPathological Complete ResponseTotal Neoadjuvant Treatment
National Taiwan University Hospital50 enrolled1 locationNCT06764355
Recruiting
Phase 1

MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)Esophageal Cancer, Squamous Cell
UMC Utrecht30 enrolled1 locationNCT07359417
Recruiting
Phase 1Phase 2

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

Ovarian CarcinomaNSCLCSCLC+5 more
Jacobio Pharmaceuticals Co., Ltd.152 enrolled1 locationNCT04686682
Recruiting
Phase 1

Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)

Esophageal Squamous Cell Carcinoma (ESCC)
Shanghai Zhongshan Hospital60 enrolled1 locationNCT07317609
Recruiting
Phase 2

The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
Hebei Medical University Fourth Hospital25 enrolled1 locationNCT07290010
Recruiting

Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma

ESCC
City of Hope Medical Center600 enrolled1 locationNCT07266363
Recruiting

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)CholangiocarcinomaHepatocellular Carcinoma (HCC)+3 more
City of Hope Medical Center1,000 enrolled1 locationNCT07224750
Recruiting
Phase 2

Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
Sun Yat-sen University134 enrolled1 locationNCT06912074
Recruiting

An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
Three Gorges Hospital of Chongqing University40 enrolled1 locationNCT07080437
Recruiting

Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma

Lymph Node MetastasisESCCRadiomics
The First Affiliated Hospital of Anhui Medical University500 enrolled1 locationNCT07050576
Recruiting
Phase 2

AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients

ESCCAdvanced Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital30 enrolled1 locationNCT06489197
Recruiting

Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France

Gastric AdenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)Gastro-esophageal Junction Adenocarcinoma+1 more
Bristol-Myers Squibb500 enrolled2 locationsNCT06504615
Recruiting
Phase 2

Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC

ImmunotherapyEsophageal Squamous Cell Carcinoma (ESCC)
Sichuan University41 enrolled1 locationNCT06603402